After 2026-01-30, Bender Jeremy's DAWN filings point to a sequence worth tracking
Bender Jeremy's DAWN insider record stands at $5.2M cumulative sales (latest filing 2026-01-30); focus on sequence, transaction-code mix, and ownership trend over time.
Bender Jeremy continues to shape the insider narrative for DAWN. Cumulative sales are $5.2M, but the higher-value insight is in how filings cluster around 2026-01-30 and after.
Recent Form 4 Prints
| Date | Code | Shares | Price | Est. Value |
|---|---|---|---|---|
| 2026-01-30 | A | 237,000 | N/A | N/A |
| 2026-01-30 | A | 355,000 | $11.16 | $4.0M |
| 2025-11-25 | G | 7,225 | N/A | N/A |
| 2025-11-25 | G | 7,225 | N/A | N/A |
| 2025-11-25 | G | 300,000 | N/A | N/A |
| 2025-11-25 | G | 300,000 | N/A | N/A |
| 2025-11-25 | G | 300,000 | N/A | N/A |
| 2025-11-25 | G | 300,000 | N/A | N/A |
Context for Day One Biopharmaceuticals, Inc.
In headline-sensitive environments, insider prints are easy to overread. A disciplined approach is to watch persistence outside expected liquidity windows.
Search-Based Context
Current search results for industry context
Bottom Line
Informative signal, not yet decisive; wait for follow-through data.
Breaking News Editor at 13F Insight. First to report on major SEC filings, institutional moves, and regulatory developments.
More from Alex →Add the funds and stocks mentioned here to a free watchlist, or get an email the next time they file — no card required.